Research programme: enzyme replacement therapies - Valerion Therapeutics

Drug Profile

Research programme: enzyme replacement therapies - Valerion Therapeutics

Alternative Names: 3E10Fab-GAA - Valerion Therapeutics; 3E10fv-MTM1 fusion protein - Valerion Therapeutics; 4s3-001; 4s3-002; 4s3-004; 4s3-005; VAL 0524; VAL-0411; VAL-0417; VAL-0620; VAL-1205

Latest Information Update: 31 Aug 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator 4s3 Bioscience
  • Developer Valerion Therapeutics
  • Class Enzymes; Proteins
  • Mechanism of Action Enzyme replacements; Protein replacements; Tumour suppressor protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Congenital structural myopathies; Myotonic dystrophy
  • Research Myoclonic epilepsies; Neurofibromatoses

Most Recent Events

  • 26 Jul 2016 Early research in Myoclonic epilepsies in USA (unspecified route) (Alopexx pipelines, July 2016)
  • 26 Jul 2016 Preclinical development is ongoing for Congenital structural myopathies and Myotonic dystrophy in USA (Alopexx pipeline, July 2016)
  • 26 Jul 2016 Early research in Neurofibromatosis in USA (unspecified route) (Alopexx pipelines, July 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top